Swelife financing towards an innovative, effective and tolerable epigenetic cancer therapy for an orphan cancer indication

*Lund, Sweden, April 2, 2020* – SARomics Biostructures, Red Glead Discovery and researchers at Sahlgrenska Cancer Center jointly collaborate in this project that was one of 15 financed by Swelife in order to increase health and well-being as well as increasing the sustainable growth and competitiveness of Swedish life science. In the project, a preclinical innovative epigenetic therapy will be significantly advanced towards clinical studies for an orphan cancer indication.

The project was earlier partly financed by SWElife in 2018 and 2019. The successful outcome from earlier activities is a clear result of the good match of the project partners’ skills and expertise. The advanced structural biology platform and drug design expertise contributed by SARomics Biostructures are combined with the medicinal chemistry skills and bioassay technologies of Red Glead Discovery. Sahlgrenska Cancer Center, via the Sahlgrenska Translational Melanoma Group (SATMEG) headed by Professor Jonas Nilsson, are recognized experts in epigenetic research with a unique translational platform and a strong ambition to develop therapies for their patients. Furthermore, Dr. Lars Ny, the clinical principal investigator affiliated with SATMEG, will coordinate clinical activities.

Björn Walse, CEO of SARomics Biostructures, said “We are excited about the continued opportunity to work with the amazing project team on this innovative project that clearly leverages the competitiveness of all partners.”

Martina Kvist Reimer, VP of Red Glead Discovery and project leader for this project, added “With this project, we want to significantly advance a preclinical innovative epigenetic therapy towards clinical studies. To be able to work in close collaboration with clinical experts from bench to bedside to deliver to the need of the patients is especially rewarding and a prerequisite for success.”

**SARomics Biostructures** provides premium services within protein crystallization, structure determination, computational chemistry and fragment-based hit generation. SARomics has built a global reputation for its structural biology skills and is currently supporting clients in Asia, Europe, North America and Scandinavia to pursue their drug discovery objectives. In parallel the company has attracted significant funding for its internal research programs and is currently involved in three research initiatives aiming at the discovery of leads for new medicines.

www.saromics.com

**Red Glead Discovery** is one of Sweden’s fastest growing companies within the Life Science area, focused on preclinical contract research (Drug Discovery) on small molecules and peptides. Since its inception in 2011, the company has served close to 200 customers globally to develop their ideas towards new drugs. The company, founded by seven employees from AstraZeneca R&D Lund, has grown to 33 employees and is located with fit-for-purpose laboratories and offices at Medicon Village in Lund, Sweden.

www.redglead.com

**Sahlgrenska Cancer Center** (SCC) is a joint effort between the Sahlgrenska Academy at University of Gothenburg and the Sahlgrenska University Hospital (SU). SCC is a cancer center focusing on translational cancer research, with the patient as a focal point. The long-term goal of the center is to improve the care of cancer patients by facilitating new scientific discoveries and translating these into clinical practice.

www.cancercenter.gu.se

**Swelife – For a competitive life science ecosystem in Sweden**

Swelife is a strategic innovation programme, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programme’s partners. We support collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.

www.swelife.se